Results 101 to 110 of about 5,494 (193)

Advancements in Alzheimer's Disease Therapy: The Role of Anti-Amyloid Monoclonal Antibodies - A Literature Review

Journal of Education, Health and Sport
Alzheimer's disease is a neurodegenerative disorder characterized by progressive cognitive decline and neuronal damage. Anti-amyloid monoclonal antibodies such as aducanumab, lecanemab, and donanemab, represent the first disease-modifying therapies for ...
Agnieszka Skoczeń, Natalia Rutecka, Błażej Kaczmarek, Agata Kuśnierz-Gibała, Adrian Kruk, Michał Kulesza, Weronika Wawrzynów, Martyna Miłoś, Aleksandra Dorosz, Magdalena Maria Jakubowska   +9 more
doaj   +1 more source

Disease Modifying Monoclonal Antibodies and Symptomatic Pharmacological Treatment for Alzheimer’s Disease

Biomedicines
Alzheimer’s Disease (AD) is an irreversible, progressive syndrome characterized by neurocognitive impairment. Two neuropathological features seen in AD are extracellular amyloid plaques consisting of amyloid beta1-40 and 1-42, and intracellular ...
Xiaoming Qi, Damir Nizamutdinov, Song Stephen Yi, Erxi Wu, Jason H. Huang   +4 more
doaj   +1 more source

Aducanumab-avwa

American Journal of Health-System Pharmacy, 2021
openaire   +2 more sources

Fit for purpose high‐throughput absolute quantitation of chimeric aducanumab in mouse cortex and plasma [PDF]

Background: Although pharmacokinetics and pharmacodynamics of biotherapeutics are commonly studied through ELISAs; however, the extremely strong binding of modern antibody‐based therapeutics result in background, inability of secondary antibody binding ...
Haynes, Kathryn A., Doud, Emma H., Quinney, Sara K., Mosley, Amber L., Silva Santos, Diogo Francisco, Sukoff Rizzo, Stacey J., Territo, Paul R.   +6 more
core   +1 more source

Detection of extracellular amyloid beta aggregates by an Aducanumab-based synNotch receptor: an in vitro proof-of-concept study

Journal of Translational Medicine
Background Synthetic Notch (synNotch) receptors are a powerful gene regulation platform that activate transcription in response to membrane-bound ligands and extracellular matrix components, with emerging applications in cancer, autoimmunity, and ...
Nicholas J. Bergo, Suckwon Lee, Cynthia J. Siebrand, Zachary Mayeri, Julie K. Andersen, Chaska C. Walton   +5 more
doaj   +1 more source

Aducanumab: una mirada dos años después de su aprobación [PDF]

Alzheimer’s disease is the leading cause of dementia worldwide and a critical public health problem. While deaths from cardiovascular diseases have decreased, those attributed to Alzheimer’s disease have increased in recent years with no curative ...
Astrid Torres, López , Norman, Camargo , Loida, Loida Camargo, Torres, Astrid, Norman López   +5 more
core   +1 more source

Lecanemab real-world treatment outcomes from cohort study in early Alzheimer's disease

Journal of Alzheimer's Disease Reports
Lecanemab has demonstrated amyloid reduction and slowed clinical decline in early Alzheimer's disease trials. Herein, we report retrospective case series results on lecanemab treatment in our clinic. Overall, 61 individuals were included.
Alyanna Ferrer, Justin Moon
doaj   +1 more source

Table1_Imaging spectrum of amyloid-related imaging abnormalities associated with aducanumab immunotherapy.docx

Alzheimer's Disease (AD) is a leading cause of morbidity. Management of AD has traditionally been aimed at symptom relief rather than disease modification.
Manoj Tanwar (17737653), C. Austin Wheeler (17737647), Parnian Shobeiri (9117877), Marissa Natelson Love (17737650), Ramin Shahidi (16805001), Zahra Saadatpour (17737644), Mohammadreza Alizadeh (17737641), Houman Sotoudeh (14786503)   +7 more
core   +1 more source

Aducanumab: The Controversial New Drug Licensed to Treat Alzheimer’s Disease [PDF]

Alzheimer’s Disease is a neurodegenerative condition that results in both cognitive and functional decline. It has a high prevalence in the developed world, accompanied by a large burden of disease.
Janes, Ava
core  

Quantitative systems pharmacology‐based exploration of relevant anti‐amyloid therapy challenges in clinical practice

Alzheimer’s & Dementia: Translational Research & Clinical Interventions
INTRODUCTION Addressing practical challenges in clinical practice after the recent approvals of amyloid antibodies in Alzheimer's disease (AD) will benefit more patients.
Hugo Geerts, Silke Bergeler, Mike Walker, Rachel H. Rose, Piet H. van derGraaf   +4 more
doaj   +1 more source